COMMUNIQUÉS West-GlobeNewswire
-
Enovis to Host Second Quarter 2026 Results Conference Call on August 6th
17/07/2026 -
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
17/07/2026 -
Damora Announces Redomestication from Delaware to Cayman Islands
17/07/2026 -
SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology
17/07/2026 -
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
17/07/2026 -
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/07/2026 -
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
17/07/2026 -
BrewDog and Tilray Brands Unlock £1 Million Bar Tab for Football Fans Across England, Scotland and Ireland
17/07/2026 -
Orion Group Half-Year Financial Report January–June 2026
17/07/2026 -
Orion Corporation’s financial reporting and Annual General Meeting in 2027
17/07/2026 -
Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline
17/07/2026 -
European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU
17/07/2026 -
Enjoin Reports 923% Average ROI Delivered in Q1 2026
17/07/2026 -
Marketing Veteran Bryan Dulaney is advising SafeSpace Global on Growth Strategy
17/07/2026 -
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
17/07/2026 -
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
16/07/2026 -
UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
16/07/2026 -
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
16/07/2026 -
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
16/07/2026
Pages